Gerresheimer AG

Gerresheimer's capital structure shows a debt-to-equity ratio of 0.85, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.01, suggesting limited short-term liquidity cushion. Free cash flow is negative at -104.43 million EUR, driven by capital expenditures of -369.85 million EUR, which outpace operating cash flow of 240.33 million EUR. Profitability metrics show a return on equity of 7.26% and a return on assets of 2.88%, both below the industry median for medical equipment firms. The net profit margin of 5.39% (109.72 million EUR net income on 2.04 billion EUR revenue) is also below the sector average, indicating room for improvement in cost control and pricing power. The company's geographic and segment exposure is concentrated in its core pharmaceutical packaging business, with no material diversification into other product lines or regions. Revenue is derived primarily from the European and North American markets, with no disclosed segment breakdown in the latest financials. Looking ahead, Gerresheimer's revenue is expected to grow modestly, with a projected increase of 2.5% in the current fiscal year and 3.0% in the next, based on analyst estimates and historical performance. However, the company's free cash flow remains negative, which could constrain its ability to fund growth initiatives without external financing. Risk factors include the company's net cash position being negative after subtracting total debt, which could limit its financial flexibility. The dilution risk is currently low, with no near-term pressure from share issuance or convertible debt. However, the company's capital expenditures are high relative to operating cash flow, which could necessitate additional financing in the future. Recent events include the publication of the latest financial results, which show a slight improvement in operating income to 197.47 million EUR from prior periods. No material changes in business strategy or regulatory environment have been disclosed in the most recent filings or transcripts.